0.9% Sodium Chloride Injection, USP

Rx only

freeflex logo

0.9% Sodium Chloride Injection, USP solution is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration.

For 0.9% Sodium Chloride Injection, USP, each 100 mL contains 900 mg sodium chloride in water for injection. Electrolytes per 1,000 mL: sodium 154 mEq; chloride 154 mEq. The osmolarity is 308 mOsmol/L (calc.).

The pH in the 100 mL and smaller containers is 6.0; for the 250 mL and larger containers, the pH is 5.6. The pH range is 4.5 to 7.0 for all containers.

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

The solution is a parenteral fluid and electrolyte replenisher.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

Water for injection, USP is chemically designated H₂O.

The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (free flex ® bag). The free flex ® + bag has a needle-free injection port and can accept standard luer lock syringes to add medication. The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.

When administered intravenously, the solution provides a source of water and electrolytes.

Solutions which provide combinations of hypotonic or isotonic concentrations of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements.

Isotonic concentrations of sodium chloride are suitable for parenteral replacement of chloride losses that exceed or equal the sodium loss. Hypotonic concentrations of sodium chloride are suited for parenteral maintenance of water requirements when only small quantities of salt are desired. A hypertonic concentration of sodium chloride may be used to repair severe salt depletion syndrome.

Sodium chloride in water dissociates to provide sodium (Na⁺) and chloride (Cl^-) ions. Sodium (Na⁺) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl^-) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na⁺) and chloride (Cl^-) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na⁺) plays a major role in maintaining physiologic equilibrium.

Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient.

None known.

Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

The intravenous administration of Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutive states is inversely proportional to the electrolyte concentration of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.

In patients with diminished renal function, administration of Sodium Chloride Injection, USP may result in sodium retention.

Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures (see WARNINGS , PRECAUTIONS, and ADVERSE REACTIONS).

The dose is dependent upon the age, weight and clinical condition of the patient.

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit (see PRECAUTIONS).

Check flexible container solution composition, lot number, and expiry date.

Do not remove solution container from its overwrap until immediately before use.

Use sterile equipment and aseptic technique.

To Open

1. Turn solution container over so that the text is face down. Using the pre-cut corner tabs, peel open the overwrap and remove solution container.
2. Check the solution container for leaks by squeezing firmly. If leaks are found, or if the seal is not intact, discard the solution.
3. Do not use if the solution is cloudy or a precipitate is present.

To Add Medication

The Additive port of the free flex ^® + container accepts standard luer lock syringes. Do not use a needle for additions.

1. Identify LIGHT BLUE Additive Port with arrow pointing toward solution container.
2. Immediately before injecting additives, break off LIGHT BLUE Additive Port Cap with the arrow pointing toward solution container.
3. Hold base of LIGHT BLUE Additive Port.
4. Attach Luer Lock syringe to the threaded LIGHT BLUE Additive Port. Inject additive.
5. Mix solution container contents thoroughly.

Preparation for Administration

1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from container.
2. Use a non-vented infusion set or close the air-inlet on a vented set.
3. Close the roller clamp of the infusion set.
4. Hold the base of BLUE Infusion Port.
5. Insert spike through BLUE Infusion Port by rotating wrist slightly until the spike is inserted.
   NOTE: See full directions accompanying administration set.

WARNING: Do not use flexible container in series connections.

0.9% Sodium Chloride Injection, USP is supplied in single-dose flexible plastic containers as follows:

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing. The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.

BD Logo

Becton, Dickinson and Company
1 Becton Drive
Franklin Lakes, NJ 07417 USA
For product inquiry: 1-800-523-0502

Distributed by BD.
Manufactured by Fresenius Kabi.

451832

Issued: August 2024

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 50 mL Bag Label

freeflex^®+
NDC 17271-771-02 50 mL
0.9% Sodium Chloride Injection, USP

For intravenous use. Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 50 mL Case Label

NDC 17271-771-02     1727177102

0.9% Sodium Chloride Injection, USP

freeflex^®+

50 mL x 60

Store at 20° to 25°C (68° to 77°F)

[see USP Controlled Room Temperature].

Protect from freezing.

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 100 mL Bag Label

freeflex^®+
NDC 17271-771-03 100 mL
0.9% Sodium Chloride Injection, USP

For intravenous use. Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 100 mL Case Label

NDC 17271-771-03     1727177103

0.9% Sodium Chloride Injection, USP

freeflex^®+

100 mL x 50

Store at 20° to 25°C (68° to 77°F)

[see USP Controlled Room Temperature].

Protect from freezing.

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 250 mL Bag Label

NDC 17271-771-05

freeflex^®+       250 mL
0.9% Sodium Chloride Injection, USP

For intravenous use. Rx only

PACKAGE LABEL - PRINCIPAL DISPLAY – 0.9% Sodium Chloride 250 mL Case Label

NDC 17271-771-05     1727177105

0.9% Sodium Chloride Injection, USP

freeflex^®+

250 mL x 30

Store at 20° to 25°C (68° to 77°F)

[see USP Controlled Room Temperature].

Protect from freezing.